G
Gayle S. Jameson
Researcher at Translational Genomics Research Institute
Publications - 64
Citations - 2533
Gayle S. Jameson is an academic researcher from Translational Genomics Research Institute. The author has contributed to research in topics: Pancreatic cancer & Gemcitabine. The author has an hindex of 18, co-authored 58 publications receiving 2035 citations. Previous affiliations of Gayle S. Jameson include Banner Health & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam,Chung-Pin Li,György Bodoky,Andrew Dean,Yan Shen Shan,Gayle S. Jameson,Teresa Macarulla,Kyung-Hun Lee,David Cunningham,Jean F Blanc,Richard A Hubner,Chang Fang Chiu,Gilberto Schwartsmann,Jens T. Siveke,Fadi Braiteh,Victor Moyo,Bruce Belanger,Navreet Dhindsa,Eliel Bayever,Daniel D. Von Hoff,Li-Tzong Chen,Li-Tzong Chen +21 more
TL;DR: Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy.
Journal ArticleDOI
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff,J. Stephenson,Peter Rosen,David M. Loesch,Mitesh J. Borad,Stephen P. Anthony,Gayle S. Jameson,Susan Brown,Nina Cantafio,Donald A. Richards,Tom R. Fitch,Ernesto Wasserman,Cristian Fernandez,Sylvan B. Green,William Sutherland,Michael L. Bittner,Arlet Alarcon,David Mallery,Robert J. Penny +18 more
TL;DR: It is possible to identify molecular targets in patients' tumors from nine different centers across the United States and in 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression.
Journal ArticleDOI
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Ramesh K. Ramanathan,Ronald L. Korn,Natarajan Raghunand,Jasgit C. Sachdev,Ronald G. Newbold,Gayle S. Jameson,Gerald J. Fetterly,Joshua Prey,Stephan G. Klinz,Jaeyeon Kim,Jason E. Cain,Bart S. Hendriks,Daryl C. Drummond,Eliel Bayever,Jonathan Fitzgerald +14 more
TL;DR: Correlation between FMX levels in tumor lesions and nal-IRI activity suggests that lesion permeability to FMX and subsequent tumor uptake may be a useful noninvasive and predictive biomarker for nal -IRI response in patients with solid tumors.
Journal ArticleDOI
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions
Wei Lin,Pawan Noel,Erkut Borazanci,Jeeyun Lee,Albert Amini,In Woong Han,Jin Seok Heo,Gayle S. Jameson,Cory Fraser,Margaux Steinbach,Yanghee Woo,Yuman Fong,Derek Cridebring,Daniel D. Von Hoff,Joon Oh Park,Haiyong Han +15 more
TL;DR: This work identifies significant heterogeneity in cellular compositions of PDAC tumors and between primary tumors and metastatic lesions, and finds that the tumor cellular composition was an important factor in defining the PDAC subtypes.
Journal ArticleDOI
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
Johann S. de Bono,Lida Mina,Michael Gonzalez,Nicola J. Curtin,Evelyn Wang,Joshua Henshaw,Manpreet Chadha,Jasgit C. Sachdev,Daniela Matei,Gayle S. Jameson,Michael Ong,Bristi Basu,Zev A. Wainberg,Lauren Averett Byers,Rashmi Chugh,Andrew Dorr,Stanley B. Kaye,Ramesh K. Ramanathan +17 more
TL;DR: BMN 673 is the most potent and specific inhibitor of PARP1/2 in clinical development (IC50<1nM) and in tumors genetically dependent on DNA repair by homologous recombination PARP inhi...